Le lymphoedème des membres supérieurs est une complication relativement fréquente après traitement du cancer du sein par chirurgie et/ou radiothérapie. L'incidence en France est de l'ordre de 3740 cas par an avec une prévalence de 37400 cas environ. Le traitement recommandé associe les...

BACKGROUND: In 2005, the French Government implemented a new way of financing high-cost drugs for hospitals in order to promote innovation. Such drugs are gathered on a positive list, established by the Ministry of Health, with a reimbursement price cap. Hospitals still negotiate with...

Background To reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes the use of unlicensed drugs on an exceptional and temporary basis...

We develop a "welfarist" model in which the collective demand for health insurance is mainly explained by a solvability motive : health insurance does not have for principal function to treat the risk aversion of solvent agents but to make it possible to individuals who are too poor to assume...